• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right?

作者信息

Liabeuf Sophie, Laville Solène M, Bieber Brian, Tu Charlotte, Stengel Bénédicte, Wong Michelle M Y, Calice da Silva Viviane, Fliser Danilo, Robinson Bruce M, Pecoits-Filho Roberto, Massy Ziad A

机构信息

Pharmacology Department, Amiens University Medical Center, Amiens, France.

MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France.

出版信息

Kidney Int Rep. 2021 Jun 12;6(9):2496-2500. doi: 10.1016/j.ekir.2021.06.004. eCollection 2021 Sep.

DOI:10.1016/j.ekir.2021.06.004
PMID:34514213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8418947/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/123a/8418947/60f2c0f308c9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/123a/8418947/a467f63eb61e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/123a/8418947/60f2c0f308c9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/123a/8418947/a467f63eb61e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/123a/8418947/60f2c0f308c9/gr2.jpg

相似文献

1
Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right?为中重度慢性肾脏病患者开具直接口服抗凝剂：剂量过少还是恰到好处？
Kidney Int Rep. 2021 Jun 12;6(9):2496-2500. doi: 10.1016/j.ekir.2021.06.004. eCollection 2021 Sep.
2
Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.与老年患者口服抗凝药物种类选择相关的因素：一项观察性研究。
J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):332-337. doi: 10.1177/1074248420917811. Epub 2020 Apr 8.
3
Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.单中心回顾性评估直接口服抗凝剂与低分子量肝素及维生素K拮抗剂在癌症患者中的安全性和有效性。
J Oncol Pharm Pract. 2019 Jan;25(1):52-59. doi: 10.1177/1078155217726158. Epub 2017 Aug 21.
4
Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.韩国非瓣膜性心房颤动患者中口服抗凝剂的应用。
Int J Clin Pharm. 2019 Dec;41(6):1434-1441. doi: 10.1007/s11096-019-00901-8. Epub 2019 Sep 14.
5
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
6
Acute subdural hematoma in patients on oral anticoagulant therapy: management and outcome.口服抗凝治疗患者的急性硬脑膜下血肿：处理和结局。
Neurosurg Focus. 2017 Nov;43(5):E12. doi: 10.3171/2017.8.FOCUS17421.
7
Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.处方正确吗？非瓣膜性心房颤动患者非维生素K拮抗剂抗凝剂（NOAC）处方的回顾。心房颤动安全处方及非维生素K口服抗凝剂在预防卒中中的评估（SAFE-NOACS）组。
Ir J Med Sci. 2019 Feb;188(1):101-108. doi: 10.1007/s11845-018-1837-7. Epub 2018 Jun 2.
8
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.非维生素 K 依赖性口服抗凝剂（NOACs）在伴有心房颤动的慢性肾脏病患者中的应用。
Thromb Res. 2017 Jul;155:38-47. doi: 10.1016/j.thromres.2017.04.027. Epub 2017 May 4.
9
[Old and new oral anticoagulants in the management of atrial fibrillation. Hungarian data].[心房颤动管理中的新型与传统口服抗凝剂。匈牙利数据]
Orv Hetil. 2017 Oct;158(39):1545-1549. doi: 10.1556/650.2017.30802.
10
[Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].非维生素K依赖型口服抗凝剂用于非瓣膜性心房颤动的慢性肾脏病患者
G Ital Nefrol. 2017 Apr;34(2):58-73.

引用本文的文献

1
Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis.直接口服抗凝剂在慢性肾脏病中的安全性和有效性：一项荟萃分析。
Res Pract Thromb Haemost. 2024 Oct 9;8(7):102584. doi: 10.1016/j.rpth.2024.102584. eCollection 2024 Oct.
2
Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.不同口服抗凝剂在伴有严重慢性肾脏病的心房颤动患者中的大出血、卒中和全身性栓塞及死亡风险。
J Am Heart Assoc. 2024 Aug 20;13(16):e034641. doi: 10.1161/JAHA.123.034641. Epub 2024 Aug 9.
3

本文引用的文献

1
Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation.口服抗凝药物处方趋势、患者特征、以及房颤患者用药依从性的决定因素。
Pharmacotherapy. 2020 Jan;40(1):40-54. doi: 10.1002/phar.2350. Epub 2019 Dec 17.
2
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.多中心随机对照试验：华法林抗凝替代物利伐沙班联合或不联合维生素 K2 在血液透析合并心房颤动患者中的应用：VALKYRIE 研究。
J Am Soc Nephrol. 2020 Jan;31(1):186-196. doi: 10.1681/ASN.2019060579. Epub 2019 Nov 8.
3
Effectiveness and safety of apixaban and rivaroxaban warfarin in patients with atrial fibrillation and chronic kidney disease.
阿哌沙班和利伐沙班相对于华法林在心房颤动合并慢性肾脏病患者中的有效性和安全性
World J Nephrol. 2023 Dec 25;12(5):132-146. doi: 10.5527/wjn.v12.i5.132.
Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
慢性肾脏病与心律失常：改善全球肾脏病预后组织（KDIGO）争议会议要点
Kidney Int. 2018 Aug;94(2):231-234. doi: 10.1016/j.kint.2018.05.005. Epub 2018 Jun 21.
4
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.慢性肾脏病与心律失常：来自改善全球肾脏病预后组织（KDIGO）争议会议的结论
Eur Heart J. 2018 Jun 21;39(24):2314-2325. doi: 10.1093/eurheartj/ehy060.
5
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.非维生素 K 拮抗剂口服抗凝剂在伴有肾功能障碍的心房颤动患者中的剂量调整。
J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790. doi: 10.1016/j.jacc.2017.03.600.
6
Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS to the CHADS-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry.在采用CHADS-VASc评分替代CHADS评分进行血栓栓塞风险评估的指南推荐更改后，低至中度卒中风险心房颤动患者口服抗凝药处方的当代趋势：来自国家心血管数据注册中心门诊实践创新与临床卓越心房颤动注册研究的分析
Circ Cardiovasc Qual Outcomes. 2017 May;10(5). doi: 10.1161/CIRCOUTCOMES.116.003476.
7
The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and Methods.CKD 结局和实践模式研究（CKDopps）：原理和方法。
Am J Kidney Dis. 2016 Sep;68(3):402-13. doi: 10.1053/j.ajkd.2016.03.414. Epub 2016 Apr 22.
8
Anticoagulation therapy: Balancing the risks of stroke and bleeding in CKD.抗凝治疗：平衡慢性肾脏病患者中风与出血的风险
Nat Rev Nephrol. 2015 Apr;11(4):200-2. doi: 10.1038/nrneph.2015.14. Epub 2015 Feb 10.
9
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.与华法林相比，利伐沙班预防非瓣膜性心房颤动合并中度肾功能不全患者的中风和全身性栓塞。
Eur Heart J. 2011 Oct;32(19):2387-94. doi: 10.1093/eurheartj/ehr342. Epub 2011 Aug 28.